How long does it take for semaglutide injection to cause hypoglycemia?

Semaglutide injection (Wegovy) was originally designed as a diabetes treatment drug, so its hypoglycemic effect has been verified in many countries. Usually within 1 to 2 weeks after starting use, patients can observe a slight decrease in fasting blood sugar and postprandial blood sugar. After continuous injection for 4 to 8 weeks, the blood sugar lowering effect will be more obvious. This is related to the gradual reaching of steady-state blood concentration of the drug in the body. As a long-acting GLP-1 receptor agonist, semaglutide has a half-life of approximately 7 days, so it can maintain stable efficacy by injecting it once a week. It improves blood glucose metabolism in multiple aspects by promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and increasing tissue sensitivity to insulin.

Unlike traditional antidiabetic drugs, the effect of semaglutide is "smooth" and does not cause rapid or severe blood sugar fluctuations, which makes it less risky for hypoglycemia. Most patients may experience a slight loss of appetite or a feeling of fullness in the stomach at the beginning of treatment, which is a natural reaction of the central anti-eating effect of the drug. Clinical observation found that after using Wegovy for about 8 to 12 weeks, not only blood sugar levels improved significantly, but also weight decreased, and some patients even showed signs of recovery of pancreatic islet function.

For non-diabetic patients, althoughWegovy is mainly used for weight control, its hypoglycemic effect will still be reflected indirectly. Obesity is often accompanied by insulin resistance and hyperinsulinemia, and Wegovy improves insulin sensitivity and maintains fasting blood sugar in a more ideal range, thereby reducing the risk of prediabetes developing into diabetes. Overseas data points out that among obese people with abnormal blood sugar, after 6 months of continuous use of Wegovy, the blood sugar indicators of more than 70% of patients returned to the normal range.

It needs to be emphasized that Wegovy’s glucose lowering speed is closely related to the patient’s basal metabolic state, dietary structure and weight changes. If patients strictly control their diet and increase exercise, their blood sugar will improve faster and more significantly.

Reference materials:https://www.drugs.com